HSE to fund Respreeza for six months

The HSE has agreed to fund the administration of Respreeza for six months.

The HSE’s decision brings to an end the current deadlock over the provision of Respreeza to a group of 21 patients who had been receiving the therapy on a “compassionate-use basis” on the conclusion of a clinical trial here.

The move will come as a major relief to patients affected by the Alpha-1 lung condition which causes emphysema and associated ...